Abivax (NASDAQ:ABVX) Now Covered by Jefferies Financial Group

Equities researchers at Jefferies Financial Group assumed coverage on shares of Abivax (NASDAQ:ABVX) in a report released on Monday. The firm set a “buy” rating and a $160.00 price target on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 38.53% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Guggenheim restated a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research report on Thursday, December 18th. Oppenheimer set a $131.00 target price on shares of Abivax in a research note on Thursday, January 8th. Truist Financial set a $140.00 price target on shares of Abivax in a report on Monday, November 24th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $136.69.

Abivax Stock Performance

Shares of ABVX stock opened at $115.50 on Monday. Abivax has a 52-week low of $4.77 and a 52-week high of $148.83. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a market cap of $9.13 billion, a PE ratio of -27.63 and a beta of 1.01. The business has a 50-day simple moving average of $118.99 and a 200-day simple moving average of $109.10.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. On average, equities analysts expect that Abivax will post -2.83 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ABVX. WPG Advisers LLC increased its holdings in Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new stake in shares of Abivax in the third quarter valued at about $36,000. Finally, Bank of Hawaii increased its stake in shares of Abivax by 14.9% during the fourth quarter. Bank of Hawaii now owns 3,454 shares of the company’s stock worth $466,000 after purchasing an additional 448 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.